The 10-second takeaway
For the quarter ended March 31 (Q3), Cardiovascular Systems beat slightly on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP loss per share grew.
Gross margins expanded, operating margins shrank, net margins dropped.
Cardiovascular Systems booked revenue of $26.5 million. The six analysts polled by S&P Capital IQ hoped for sales of $26.0 million on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $21.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.29. The six earnings estimates compiled by S&P Capital IQ averaged -$0.31 per share. GAAP EPS were -$0.29 for Q3 compared to -$0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 76.4%, 60 basis points better than the prior-year quarter. Operating margin was -20.4%, 290 basis points worse than the prior-year quarter. Net margin was -23.5%, 370 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $27.1 million. On the bottom line, the average EPS estimate is -$0.29.
Next year's average estimate for revenue is $101.6 million. The average EPS estimate is -$1.11.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 11 members out of 16 rating the stock outperform, and five members rating it underperform. Among two CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give Cardiovascular Systems a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cardiovascular Systems is buy, with an average price target of $22.10.
Is Cardiovascular Systems the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cardiovascular Systems to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.